Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    regorafenib AND GIST | Open Studies
Show Display Options
Download search resultsDownload the search results for:
regorafenib AND GIST | Open Studies (5 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: Sunitinib;   Drug: Regorafenib
2 Recruiting Regorafenib Post-marketing Surveillance in Japan
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
3 Recruiting A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Conditions: Liposarcoma;   Osteogenic Sarcoma;   Ewing/Ewing-like Sarcoma
Interventions: Drug: Regorafenib;   Drug: Placebo
4 Recruiting Stivarga Regulatory Post-Marketing Surveillance Study in Korea
Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (Stivarga,BAY73-4506)
5 Recruiting FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
Conditions: Esophageal Cancer;   Gastric Cancer
Interventions: Drug: Regorafenib;   Drug: 5-Fluorouracil;   Drug: Leucovorin;   Drug: Oxaliplatin

Indicates status has not been verified in more than two years